<DOC>
	<DOC>NCT02980692</DOC>
	<brief_summary>This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of SUNPG1623</brief_summary>
	<brief_title>Efficacy and Safety Study of SUNPG1623</brief_title>
	<detailed_description />
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<criteria>Subject has provided written informed consent Subject is ≥ 18 years of age at time of Screening Subject must be on stable dose of NSAID for ≥ 4 weeks prior to initiation of IMP Subject has a negative evaluation for TB within 4 weeks before initiating IMP Subject has a planned surgical intervention between Baseline and the Week 24 evaluation for a pretreatment condition Subject has an active infection or history of infections Subject has any concurrent medical condition or uncontrolled, clinically significant systemic disease Subject has a known history of infection with hepatitis B, hepatitis C, or human immunodeficiency virus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>